Antimicrobial pharmacodynamics

Medical Clinics of North America

Volumn 84, Issue 6, 2000, Pages 1431-1446

  Ambrose, Paul G ^a,b   Owens Jr , Robert C ^c,d   Grasela, Dennis ^e  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b Princeton Corporate Center   (United States)

^c MAINE MEDICAL CENTER   (United States)

^d UNIVERSITY OF VERMONT   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; BACITRACIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; CREATININE; GATIFLOXACIN; GENTAMICIN; GLYCOPEPTIDE; LEVOFLOXACIN; MACROLIDE; METRONIDAZOLE; OXAZOLIDINEDIONE DERIVATIVE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN; SULTAMICILLIN; TOBRAMYCIN;

ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; HUMAN; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0033647253     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(05)70296-0     Document Type: Article

References (51)

1. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides
2. Effect of pharmacokinetic and microbiological variability on the pharmacodynamics of gatifloxacin and levofloxacin against Streptococcus pneumoniae
3. New antibiotics in pulmonary/critical care medicine: Focus on advanced generation quinolones and cephalosporins
4. New generation fluoroquinolones: With particular attention to levofloxacin
5. Continuous vs. intermittent infusion of cefuroxime for the treatment of community-acquired pneumonia
6. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides
7. Single or multiple daily doses of aminoglycosides: A meta-analysis
8. Once-daily dosing of aminoglycosides
9. Comparative study of enoxacin and netilmicin in a pharmacodynamic model to determine the importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance
10. Principles of good practice for the use of Monte Carlo techniques in human health and ecological risk assessments
11. Enterobacter bacteremia: Clinical features and emergence of antibiotic resistance during therapy
12. National survey of extended-interval aminoglycoside dosing
13. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins
14. Pharmacodynamic/pharmacokinetic parameters: Rationale for bacterial dosing of mice and men
15. Postantibiotic effect
16. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis
17. Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones
18. Effect of schedule of administration on therapeutic efficacy of penicillin: Importance of aggregate time penicillin remains at effectively bactericidal levels
19. Continuous vs. discontinuous therapy with penicillin
20. Effective concentrations of penicillin in vitro and in vivo for streptococci and pneumococci, and treponema
21. Fungalcidal effect of amphotericin B in urine: In vitro study to assess feasibility of bladder washout for localization of site of candiduria
22. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
23. Aminoglycosides: Single or multiple daily dosing? A meta-analysis on efficacy and safety
24. Once-daily aminoglycoside dosing in immunocompetent adults: A meta-analysis
25. Pharmacoeconomic impact of a once-daily aminoglycoside program
26. Antimicrobial activity of gatifloxacin, a newer 8-methoxy fluoroquinolone, tested against over 23,000 recent clinical isolates from the SENTRY antimicrobial surveillance program
27. Use of time-kill technique for susceptibility testing of Trichomonas vaginalis
28. Pharmacodynamic comparisons of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in an in vitro model of infection
29. The scientific status of pharmacology
30. Levaquin package insert
31. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae
32. Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis
33. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimum inhibitory concentration
34. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses
35. Experience with a once-daily aminoglycoside program administered to 2184 adult patients
36. Bactericidal activity of cephalosporins in an invitro model simulating serum levels
37. Ceftazidime to cefepime formulary switch: Pharmacodynamic and pharmacoeconomic rationale
38. Bactericidal activities of ceftriaxone IM, ceftriaxone IV, and cefixime PO against typical community-acquired respiratory tract pathogens
39. Once-daily vs. continuous aminoglycoside dosing: Efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin
40. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection
41. Pharmacodynamics of levofloxacin
42. Clinical pharmacology: The scientific basis of therapeutics
43. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity
44. Double-blind randomized study of 1 g versus 2 g intravenous ceftriaxone daily in the therapy of community-acquired infections
45. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy
46. Monte Carlo techniques for quantitative uncertainty analysis in public health risk assessments
47. Aminoglycoside ototoxicity: Influence of dosage regimen on drug uptake and correlation between membrane binding and some clinical features
48. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin
49. Activity of levofloxacin against penicillin-resistant Streptococcus pneumoniae in normal and neutropenic mice
50. The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity and antibacterial efficacy in a rat model of subcutaneous abscess